Literature DB >> 8174107

Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor.

D Malkin1, E Sexsmith, H Yeger, B R Williams, M J Coppes.   

Abstract

Mutations of the p53 tumor suppressor gene occur frequently in a variety of adult-onset tumors, including colon, breast, lung, and brain, yet are infrequently identified in pediatric malignancies. Wilms' tumor, a common solid tumor of childhood, can be associated with mutations of the WT1 gene. Alterations of the p53 gene have been shown to modulate the ability of WT1 to transactivate its targets. Although positive p53 immunostaining has been demonstrated in Wilms' tumors, the correlation to p53 gene mutations is not clear. We examined Wilms' tumor samples for p53 mutations utilizing polymerase chain reaction-single-strand conformation polymorphism analysis and single-strand DNA sequencing. Mutations in the coding region of the p53 gene were demonstrated in 2 of 21 (9.5%) Wilms' tumors. Each mutation yielded a substitution of amino acid residues. One mutation was located in exon 6 and the other in exon 7. Both mutations were found in tumors from patients with advanced stage disease. Focal anaplasia was demonstrated in one of these tumors. Our data suggest that although p53 mutations occur infrequently in Wilms' tumor, they may be associated with advanced disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8174107

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.

Authors:  A K Charles; K W Brown; P J Berry
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

2.  A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1.

Authors:  R W Johnstone; R H See; S F Sells; J Wang; S Muthukkumar; C Englert; D A Haber; J D Licht; S P Sugrue; T Roberts; V M Rangnekar; Y Shi
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

3.  Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.

Authors:  Min H Kang; C Patrick Reynolds; E Anders Kolb; Richard Gorlick; Hernan Carol; Richard Lock; Stephen T Keir; John M Maris; Jianwrong Wu; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2016-05-30       Impact factor: 3.167

4.  Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome.

Authors:  C Lahoti; P Thorner; D Malkin; H Yeger
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

5.  Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group.

Authors:  Ariadne H A G Ooms; Samantha Gadd; Daniela S Gerhard; Malcolm A Smith; Jaime M Guidry Auvil; Daoud Meerzaman; Qing-Rong Chen; Chih Hao Hsu; Chunhua Yan; Cu Nguyen; Ying Hu; Yussanne Ma; Zusheng Zong; Andrew J Mungall; Richard A Moore; Marco A Marra; Vicki Huff; Jeffrey S Dome; Yueh-Yun Chi; Jing Tian; James I Geller; Charles G Mullighan; Jing Ma; David A Wheeler; Oliver A Hampton; Amy L Walz; Marry M van den Heuvel-Eibrink; Ronald R de Krijger; Nicole Ross; Julie M Gastier-Foster; Elizabeth J Perlman
Journal:  Clin Cancer Res       Date:  2016-10-04       Impact factor: 12.531

6.  Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program.

Authors:  Hernan Carol; C Patrick Reynolds; Min H Kang; Stephen T Keir; John M Maris; Richard Gorlick; E Anders Kolb; Catherine A Billups; Brian Geier; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Pediatr Blood Cancer       Date:  2012-07-02       Impact factor: 3.167

Review 7.  Identifying novel therapeutic agents using xenograft models of pediatric cancer.

Authors:  Raushan T Kurmasheva; Peter J Houghton
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-18       Impact factor: 3.333

8.  Differential expression of E-cadherin and beta catenin in primary and metastatic Wilms's tumours.

Authors:  J Alami; B R Williams; H Yeger
Journal:  Mol Pathol       Date:  2003-08

9.  Stratification of Wilms tumor by genetic and epigenetic analysis.

Authors:  Richard H Scott; Anne Murray; Linda Baskcomb; Clare Turnbull; Chey Loveday; Reem Al-Saadi; Richard Williams; Fin Breatnach; Mary Gerrard; Juliet Hale; Janice Kohler; Pablo Lapunzina; Gill A Levitt; Sue Picton; Barry Pizer; Milind D Ronghe; Heidi Traunecker; Denise Williams; Anna Kelsey; Gordan M Vujanic; Neil J Sebire; Paul Grundy; Charles A Stiller; Kathy Pritchard-Jones; Jenny Douglas; Nazneen Rahman
Journal:  Oncotarget       Date:  2012-03

10.  Study of histopathological features and proliferation markers in cases of Wilms' tumor.

Authors:  Ram Narayan Das; Uttara Chatterjee; Swapan K Sinha; Ashoke K Ray; Koushik Saha; Sugato Banerjee
Journal:  Indian J Med Paediatr Oncol       Date:  2012-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.